In summary, our study mapped peripheral immune cells of RRMS and SPMS patients and provided an evidence for the involvement of cytotoxic CD8 + TEMRA with clonal expansion in MS progression, which could be used as a diagnostic biomarker for distinguishing SPMS from RRMS. Here, CD8A is linked to relapsing-remitting multiple sclerosis.